ES2647223T3 - Vapendavir para el alivio de los síntomas del asma en un sujeto que tiene una infección por el VRH - Google Patents

Vapendavir para el alivio de los síntomas del asma en un sujeto que tiene una infección por el VRH Download PDF

Info

Publication number
ES2647223T3
ES2647223T3 ES11768285.6T ES11768285T ES2647223T3 ES 2647223 T3 ES2647223 T3 ES 2647223T3 ES 11768285 T ES11768285 T ES 11768285T ES 2647223 T3 ES2647223 T3 ES 2647223T3
Authority
ES
Spain
Prior art keywords
ethoxy
piperidin
benzo
isoxazole
methylpyridazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11768285.6T
Other languages
English (en)
Spanish (es)
Inventor
John Nicholas Lambert
Jane Ryan
Janet Marie Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biota Scientific Management Pty Ltd
Original Assignee
Biota Scientific Management Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010901601A external-priority patent/AU2010901601A0/en
Application filed by Biota Scientific Management Pty Ltd filed Critical Biota Scientific Management Pty Ltd
Application granted granted Critical
Publication of ES2647223T3 publication Critical patent/ES2647223T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES11768285.6T 2010-04-15 2011-04-14 Vapendavir para el alivio de los síntomas del asma en un sujeto que tiene una infección por el VRH Active ES2647223T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2010901601 2010-04-15
AU2010901601A AU2010901601A0 (en) 2010-04-15 Compound for the treatment of respiratory condition or disease
PCT/AU2011/000434 WO2011127538A1 (en) 2010-04-15 2011-04-14 Compound for treatment of respiratory condition or disease

Publications (1)

Publication Number Publication Date
ES2647223T3 true ES2647223T3 (es) 2017-12-20

Family

ID=44788654

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11768285.6T Active ES2647223T3 (es) 2010-04-15 2011-04-14 Vapendavir para el alivio de los síntomas del asma en un sujeto que tiene una infección por el VRH

Country Status (16)

Country Link
US (1) US20110257192A1 (OSRAM)
EP (1) EP2558097B1 (OSRAM)
JP (1) JP6148618B2 (OSRAM)
KR (1) KR20130106267A (OSRAM)
CN (2) CN102844032A (OSRAM)
AU (1) AU2011241478B2 (OSRAM)
BR (1) BR112012026244A2 (OSRAM)
CA (1) CA2796207A1 (OSRAM)
EA (1) EA025224B1 (OSRAM)
ES (1) ES2647223T3 (OSRAM)
IL (1) IL222244A0 (OSRAM)
MX (1) MX2012011938A (OSRAM)
NZ (1) NZ603040A (OSRAM)
SG (2) SG184430A1 (OSRAM)
WO (1) WO2011127538A1 (OSRAM)
ZA (1) ZA201207696B (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110229140B (zh) 2013-04-12 2022-06-10 制药有限责任公司 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法
US9802926B2 (en) 2014-06-20 2017-10-31 Aviragen Therapeutics, Inc. Anhydrous crystalline free base form of 6-{2-[1 -(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole
WO2024192151A2 (en) * 2023-03-13 2024-09-19 Altesa BioSciences, Inc. Method of dosing vapendavir to treat enterovirus infections

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR213700A0 (en) * 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
CA2475971A1 (en) * 2002-02-14 2003-08-21 Viropharma Incorporated Methods of reducing rhinovirus contagion and related compositions
DE602004014728D1 (de) * 2003-02-21 2008-08-14 Apodemus Ab Behandlung von durch das ljungan-virus ausgelösten erkrankungen durch verwendung von pleconaril
US9308199B2 (en) * 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
WO2006029182A2 (en) * 2004-09-07 2006-03-16 The La Jolla Institute For Molecular Medicine Use of mdl-100,907 for treatment of allergic and eosinophil mediated diseases
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
CA2725618C (en) * 2008-05-27 2016-04-12 Biota Scientific Management Pty Ltd Antiviral salts
TW201016215A (en) * 2008-07-17 2010-05-01 Schering Corp Compositions and uses of antiviral active pharmaceutical agents

Also Published As

Publication number Publication date
MX2012011938A (es) 2013-01-28
ZA201207696B (en) 2014-03-26
EA201201416A1 (ru) 2013-03-29
US20110257192A1 (en) 2011-10-20
WO2011127538A1 (en) 2011-10-20
NZ603040A (en) 2015-03-27
AU2011241478A1 (en) 2012-11-01
AU2011241478B2 (en) 2016-12-01
SG184430A1 (en) 2012-11-29
EP2558097A4 (en) 2013-09-11
IL222244A0 (en) 2012-12-31
JP6148618B2 (ja) 2017-06-14
EP2558097A1 (en) 2013-02-20
CN105560245A (zh) 2016-05-11
KR20130106267A (ko) 2013-09-27
JP2013523844A (ja) 2013-06-17
SG10201502391WA (en) 2015-05-28
BR112012026244A2 (pt) 2016-07-12
CA2796207A1 (en) 2011-10-20
EA025224B1 (ru) 2016-12-30
EP2558097B1 (en) 2017-10-25
CN102844032A (zh) 2012-12-26

Similar Documents

Publication Publication Date Title
US11324708B1 (en) Niclosamide formulations for treating disease
US20240245690A1 (en) Treatment of Respiratory Diseases
JP6567781B2 (ja) ウイルス感染症の治療用チアゾリド化合物
IL296909A (en) Formulation
CN117695284B (zh) 冠状病毒感染的治疗
TW202200134A (zh) 治療病毒感染、器官損傷及相關症狀之方法
JP2024545086A (ja) 抗ウイルス治療剤及びその使用
ES2647223T3 (es) Vapendavir para el alivio de los síntomas del asma en un sujeto que tiene una infección por el VRH
US20240285643A1 (en) Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof in a subject having influenza and a severe influenza condition
Zyryanov et al. Pharmacotherapy for acute respiratory infections caused by influenza viruses: current possibilities
ES2939148T3 (es) Combinaciones de inhibidores de la replicación del virus de la influenza
ES2937145T3 (es) Azelastina como tratamiento antiviral
Eedara et al. Pulmonary drug delivery
US20220000808A1 (en) Cysteamine for the Treatment, Mitigation and Prevention of Coronaviral, e.g., SARS-CoV-2, Infections
KR102875179B1 (ko) 폴리클로날 면역글로불린을 사용한 급성 악화를 예방하거나 치료하기 위한 방법 및 조성물
CN115443126A (zh) 用于预防或治疗SARS-CoV-2感染的相容性溶质
CN115697301A (zh) 用于治疗急性呼吸窘迫综合征、哮喘或变应性鼻炎的制剂和方法
CN108926707A (zh) Pf4的抗rsv应用
JP2023520929A (ja) コロナウイルス感染症の処置のための方法
WO2022204397A1 (en) Treatment of long haulers syndrome with niclosamide
JP2023016055A (ja) インフルエンザおよび重篤なインフルエンザ状態を有する対象者における、置換された多環性ピリドン誘導体およびそのプロドラッグを使用したインフルエンザの治療
Saha et al. Inhaled Dry Powder of Antiviral Agents: A Promising Approach to Treating Respiratory Viral Pathogens
HK40058742B (zh) 呼吸性疾病的治疗
JP2004352712A (ja) インフルエンザの予防または治療剤